FindTrial
Sign In

Placebo (Part I)

DRUG3 trials

Sponsors

Bial - Portela C S.A., Merck Sharp & Dohme LLC, Mineralys Therapeutics Inc.

Conditions

Alzheimer's DiseaseHypertension, RenalPartial Epilepsy

Phase 2

An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)
TerminatedNCT01739348
Merck Sharp & Dohme LLCAlzheimer's Disease
Start: 2012-11-30End: 2017-04-14Updated: 2018-10-24
Trial on the Safety and Efficacy of MLS-101 in Patients With Uncontrolled Hypertension
CompletedNCT05001945
Mineralys Therapeutics Inc.Hypertension, Renal
Start: 2021-07-01End: 2022-10-07Updated: 2024-01-05

Phase 3

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy
CompletedNCT00957372
Bial - Portela C S.A.Partial Epilepsy
Start: 2004-12-31End: 2008-06-30Updated: 2014-07-02

Related Papers

Pooled Modeling of Disease Progression in Two BACE1 Inhibitor Verubecestat Trials in Prodromal to Moderate Alzheimer’s Disease
Alzheimer s & Dementia2023-12-01
Aldosterone Synthase Inhibition With Lorundrostat for Uncontrolled Hypertension
JAMA2023-09-10155 citations
Evaluation of <sup>18</sup>F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amlyoid load in Alzheimer's disease.
2022-07-078 citations
A Model-Based Approach to Bridging Plasma and Dried Blood Spot Concentration Data for Phase 3 Verubecestat Trials.
2022-04-063 citations
An Investigation of Instability in Dried Blood Spot Samples for Pharmacokinetic Sampling in Phase 3 Trials of Verubecestat.
2022-04-062 citations
Retinal Optical Coherence Tomography Metrics Are Unchanged in Verubecestat Alzheimer’s Disease Clinical Trial but Correlate with Baseline Regional Brain Atrophy
Journal of Alzheimer s Disease2020-11-2535 citations
BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain
Brain2020-09-2973 citations
Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study.
2020-05-1480 citations
Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease
Alzheimer s Research & Therapy2019-08-0675 citations
Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study
Alzheimer s Research & Therapy2018-08-22106 citations
P1‐038: VERUBECESTAT PHARMACOKINETIC AND EXPOSURE‐RESPONSE RESULTS FROM EPOCH: A PHASE 3 TRIAL IN MILD‐TO‐MODERATE ALZHEIMER'S DISEASE
Alzheimer s & Dementia2018-07-01
Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease
New England Journal of Medicine2018-05-02650 citations
POTENTIAL THERAPEUTIC BENEFITS OF DECREASING Aβ PRODUCTION THROUGH BACE INHIBITION
Innovation in Aging2017-06-30
P2‐014: Relationship Between Volumetric MRI Parameters, APOE4 and MMSE Status at Baseline in The Verubecestat (MK‐8931) Mild to Moderate Alzheimer’s Disease Phase 2/3 Trial
Alzheimer s & Dementia2016-07-011 citations
P4‐380: BACE Inhibitor Verubecestat (MK‐8931): Baseline Characteristics for Participants Enrolled in the Phase II/III Epoch Alzheimer’S Disease Trial
Alzheimer s & Dementia2016-07-01